"When determining which code you should use, you must consider your Medicare carrier’s published rules and commercial payer processing policies," write Jonathan Rubenstein, MD, and Mark Painter.

Patients with high P-CARE scores had an increased risk of any, metastatic, and fatal prostate cancer compared with patients with median P-CARE scores.

Kiwi extract, a natural collagenase, offers a medium-effect therapy with fewer side effects compared to Xiaflex. Peptides show potential as collagenase agents, but their safety profile is currently ...

GET improves emotional and psychological outcomes in young Latino testicular cancer survivors, reducing anxiety and depressive symptoms. Significant improvements in goal navigation, goal blockage, and ...

In this video, Jason M. Hafron, MD, explains how PSMA-PET has enabled the use of more targeted treatment approaches in the management of oligometastatic prostate cancer. Hafron is the chief medical ...

In this video, Tim A. Richardson, MD, shares his thoughts on the need for more genetic testing in prostate cancer as more targeted therapies become available. Richardson is the director of the ...

"I joke that on face value, the APPs work for me, but I feel like I'm really working for them, because they basically do everything except for the surgery," says Andrew Y. Sun, MD.

The SOLAR-RECUR trial evaluates copper Cu 64 PSMA I&T PET/CT for detecting biochemical recurrence in prostate cancer post-treatment. The trial enrolled 235 patients, focusing on detection and ...

The revised policy will take effect on January 1, 2025.

Patient-reported outcomes are crucial in evaluating the success of treatments for stress urinary incontinence in men. The artificial urinary sphincter significantly improves emotional health, reducing ...

Capivasertib with abiraterone and ADT significantly extended rPFS in PTEN-deficient mHSPC patients compared to placebo in the CAPItello-281 trial. The trial showed a trend toward improved overall ...